9) Subsequent Events

Debt, Preferred, Common Stock, and Option activity

From July 1, 2024, through February 7, 2025, the Company issued four (4) convertible loans for approximately $1,912,199, which each carry a 0-10% annual interest rate and one (1) to twelve (12) month terms. All the loans are convertible into common stock either at $2.50 per share or subject to a conversion adjustment. In addition, the company issued two (2) non-convertible loans for approximately $1,719,507, which carry one (1) to eight (8) month terms.

The Company also extended six (6) loans in the amount of approximately $2,500,000 to between July 1, 2024 and February 6, 2025.

From July 1, 2024, through February 7, 2025, 328 shares of Series BB convertible preferred stock converted into 3,276,668 shares of common stock, 331 shares of Series BBX convertible preferred stock were issued for debt, 160 shares of Series BBX convertible preferred stock were issued for loan extensions, 360 shares of Series BB convertible preferred stock were issued for loan extensions and 421 shares of Series BB convertible stock for default and paid-in-kind.

From July 1, 2024, through February 7, 2025, 65,000 shares of common stock were issued for loan extensions, 10,462,872 shares issued for default and paid-in-kind and 1,219,403 shares of common stock for dividends paid-in-kind. As of January 31, 2025, there were approximately 28.1 million shares of common stock not issued to shareholders.

 On January 23, 2025 the company received an insurance settlement payment in the amount of $282,761 as it related to the company’s Vegalab subsidiary and a former employee’s misconduct.